Sensitivity of polar and temperate marine organisms to oil components.

Environ Sci Technol

Radboud University Nijmegen, Institute for Water and Wetland Research, Department of Environmental Science, NL-6500 GL, Nijmegen, The Netherlands.

Published: October 2011

Potential contamination of polar regions due to increasing oil exploitation and transportation poses risks to marine species. Risk assessments for polar marine species or ecosystems are mostly based on toxicity data obtained for temperate species. Yet, it is unclear whether toxicity data of temperate organisms are representative for polar species and ecosystems. The present study compared sensitivities of polar and temperate marine species to crude oil, 2-methyl-naphthalene, and naphthalene. Species sensitivity distributions (SSDs) were constructed for polar and temperate species based on acute toxicity data from scientific literature, reports, and databases. Overall, there was a maximum factor of 3 difference in sensitivity to oil and oil components, based on the means of the toxicity data and the hazardous concentrations for 5 and 50% of the species (HC₅ and HC₅₀) as derived from the SSDs. Except for chordates and naphthalene, polar and temperate species sensitivities did not differ significantly. The results are interpreted in the light of physiological characteristics, such as metabolism, lipid fraction, lipid composition, antioxidant levels, and resistance to freezing, that have been suggested to influence the susceptibility of marine species to oil. As a consequence, acute toxicity data obtained for temperate organisms may serve to obtain a first indication of risks in polar regions.

Download full-text PDF

Source
http://dx.doi.org/10.1021/es202296aDOI Listing

Publication Analysis

Top Keywords

toxicity data
20
polar temperate
16
marine species
16
data temperate
12
temperate species
12
species
10
temperate marine
8
oil components
8
polar regions
8
species ecosystems
8

Similar Publications

Immune checkpoint inhibitor (ICI) treatment has proven successful for advanced melanoma, but is associated with potentially severe toxicity and high costs. Accurate biomarkers for response are lacking. The present work is the first to investigate the value of deep learning on CT imaging of metastatic lesions for predicting ICI treatment outcomes in advanced melanoma.

View Article and Find Full Text PDF

Here we report results of a phase 1 multi-institutional, open-label, dose-escalation trial (NCT02744287) of BPX-601, an investigational autologous PSCA-directed GoCAR-T® cell product containing an inducible MyD88/CD40 ON-switch responsive to the activating dimerizer rimiducid, in patients with metastatic pancreatic (mPDAC) or castration-resistant prostate cancer (mCRPC). Primary objectives were to evaluate safety and tolerability and determine the recommended phase 2 dose/schedule (RP2D). Secondary objectives included the assessment of efficacy and characterization of the pharmacokinetics of rimiducid.

View Article and Find Full Text PDF

Background: Dual inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) has been shown to be an effective treatment strategy in many cancers. We sought to determine the objective response rate of combination durvalumab (D) plus tremelimumab (TM) in parallel cohorts of patients with carefully selected rare cancer types in which these agents had not previously been evaluated in phase II trials and for which there was clinical or biological rationale for dual immune checkpoint inhibitor therapy to be active.

Methods: We designed a multi-centre, non-blinded, open-label phase II basket trial with each of the following 8 rare cancers considered a separate phase II trial: salivary carcinoma, carcinoma of unknown primary (CUP) with tumour infiltrating lymphocytes and/or expressing PD-L1, mucosal melanoma, acral melanoma, osteosarcoma, undifferentiated pleomorphic sarcoma, clear cell carcinoma of the ovary (CCCO) or squamous cell carcinoma of the anal canal (SCCA).

View Article and Find Full Text PDF

Background: The impact of steroid-sparing immunosuppressive agents (SSIAs) for immune-related adverse events (irAEs) on tumor outcome is not well-known. This systematic review evaluates tumor outcomes for corticosteroid (CS) monotherapy versus CS with SSIA (CS-SSIA) for irAE treatment with a focus on melanoma.

Methods: Search was conducted through 1/5/23 using PubMed, Embase, Cochrane CENTRAL, and Web of Science.

View Article and Find Full Text PDF

This dataset comprises information about 1242 lung cancer patients collected by the Medical Oncology Department of the Puerta de Hierro University Hospital of Majadahonda in Madrid, Spain. It includes information about cancer diagnosis and treatment, as well as personal and medical data recorded during anamneses. The dataset could assist in data analysis with the aim of discovering relationships between the applied treatment(s), the evolution of the disease and the associated adverse effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!